ALGS — Aligos Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$6.26
+$0.17 (+2.79%)
Aligos Therapeutics Inc (ALGS) is a biotechnology company listed on NASDAQ. It is led by Lawrence M. Blatt MBA, Ph.D., based in One Corporate Drive, South San Francisco, CA, United States, 94080, with about 70 employees. Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest reported ALGS revenue for 2025-09-30 was $741.0K. Net income was -$31.5M. Revenue was down 23.2% from 2025-06-30 to 2025-09-30. ALGS currently screens at market cap $44.1M.
Use this ALGS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALGS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALGS SEC filings page. Lician reads the product cache first so this HTML stays unique to Aligos Therapeutics Inc even when a live quote feed is slow.
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
ALGS Key Statistics
Market Cap
$44.09M
Volume
87,228
Previous Close
$6.93
Day Range
$6.85 – $7.54
EPS
-$20.94
Revenue
$3.61M
Net Income
-$131.21M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-41.7%
Profit Margin
-3633.6%
Employees
70
ALGS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $3.61M | $6.19M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$131.21M | -$87.68M | -$96.05M | -$128.33M |
| EPS (Diluted) | -$20.94 | -$34.20 | -$2.25 | $0.00 |
Total Assets
$70.09M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$37.00M
Operating Cash Flow
-$80.74M
Free Cash Flow
$0.00
Aligos Therapeutics Inc Company Information
- CEO, President & Chairman of the Board
- Lawrence M. Blatt MBA, Ph.D.
- Headquarters
- One Corporate Drive, South San Francisco, CA, United States, 94080
- Website
- www.aligos.com
- Phone
- 800-466-6059
- IPO / Founded
- 2020-10-16
- Sector
- Healthcare
- Industry
- Biotechnology